SCHEMBL5855260

SCHEMBL5855260

Cc1oc(-c2ccccc2)nc1CCCCCCOC(C)(C)CO

nearest known ligand 0.74

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 17/20 0.74
PPARG P37231 16/20 0.74
PPARD Q03181 5/20 0.74
KDM4E B2RXH2 1/20 0.48
HRH3 Q9Y5N1 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5855707 0.89 PPARG (0.60) PPARAPPARGPPARD
SCHEMBL5857233 0.89 PPARA (0.59) PPARAPPARGPPARD
SCHEMBL5857062 0.85 PPARA (1.00) PPARAPPARGPPARD
SCHEMBL5855953 0.85 PPARA (1.00) PPARAPPARGPPARD
SCHEMBL5858178 0.85 PPARA (1.00) PPARAPPARGPPARD
SCHEMBL5856037 0.82 PPARG (0.82) PPARAPPARGPPARDKDM4E
SCHEMBL5857695 0.82 PPARG (0.82) PPARAPPARGPPARDKDM4E
SCHEMBL5855374 0.82 PPARG (0.82) PPARAPPARGPPARDKDM4E
SCHEMBL7084006 0.81 PPARA (0.67) PPARAPPARGPPARDKDM4EHRH3
SCHEMBL5857599 0.81 PPARG (0.62) PPARAPPARGPPARDKDM4EHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7022723-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-04 US claimed
EP-1634876-A2 Heterocyclic compounds for the treatment of hyperlipidemia agents Nippon Shinyaku Co., Ltd. (JP) 2006-03-15 EP claimed
US-20050009892-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2005-01-13 US claimed
US-20030166697-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2003-09-04 US claimed
EP-1295875-A1 HETEROCYCLIC COMPOUNDS Nippon Shinyaku Co., Ltd. (JP) 2003-03-26 EP claimed
US-7144906-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-12-05 US disclosed
US-7030143-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-18 US disclosed
US-7022723-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-04-04 US disclosed
EP-1634876-A2 Heterocyclic compounds for the treatment of hyperlipidemia agents Nippon Shinyaku Co., Ltd. (JP) 2006-03-15 EP disclosed
US-6998412-B2 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2006-02-14 US disclosed
US-20050009785-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2005-01-13 US disclosed
US-20050009892-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2005-01-13 US disclosed
US-20040162325-A1 Heterocyclic compounds KUWABARA KENJI (JP) 2004-08-19 US disclosed
US-20030166697-A1 Heterocyclic compounds NIPPON SHINYAKU CO., LTD. (JP) 2003-09-04 US disclosed
EP-1295875-A1 HETEROCYCLIC COMPOUNDS Nippon Shinyaku Co., Ltd. (JP) 2003-03-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050009785-A1 Heterocyclic compounds LIPC, GPR119, APOB PPARA 464/4885PPARG 393/4885PPARD 912/4885
US-20050009892-A1 Heterocyclic compounds GPR119, LIPC, LIPE PPARA 579/4885PPARG 603/4885PPARD 646/4885
US-20040162325-A1 Heterocyclic compounds LIPE, GPR119, LIPC PPARA 660/4885PPARG 701/4885PPARD 875/4885
US-20030166697-A1 Heterocyclic compounds LIPE, GPR119, LIPC PPARA 660/4885PPARG 701/4885PPARD 875/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.